EMA begins review of GSK/Vir s COVID-19 antibody pharmatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from pharmatimes.com Daily Mail and Mail on Sunday newspapers.
GSK discontinues two feladilimab trials in head and neck cancer
Decision made after recommendation from Independent Data Monitoring Committee
British drugmaker GlaxoSmithKline (GSK) has announced that it will discontinue two phase 2 trials evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab.
In a statement issued today, GSK said that following a recommendation by the Independent Data Monitoring Committee, it will stop enrolling patients in the phase 2 INDUCE-3 trial – including discontinuing treatment with the ICOS agonist.
The mid-stage study is evaluating feladilimab – GSK3359609 – plus Merck & Co’s Keytruda (pembrolizumab) compared with placebo plus Keytruda for the potential treatment of patients with PD-L1 positive advanced or metastatic head and neck squamous cell carcinoma (HNSCC).
GSK decides to halt mid-stage feladilimab studies
15th April 2021
GlaxoSmithKline (GSK) has announced that it will stop enrolling patients into trials evaluating its investigational inducible T cell co-stimulatory (ICOS) agonist feladilimab.
The British drugmaker has taken the decision to halt enrolment into the Phase II INDUCE-3 trial, following a recommendation from the Independent Data Monitoring Committee, the company said in a statement.
The INDUCE-3 study was designed to evaluate feladilimab as part of a combination treatment alongside Merck & Co’s Keytruda (pembrolizumab), versus placebo plus Keytruda.
The benefit of the ICOS agonist plus Keytruda was being evaluated as a treatment for patients with PD-L1 positive recurrent locally advanced or metastatic head and neck squamous cell carcinoma in this trial.
of patients with early-stage EGFR-mutated lung cancer Tagrisso is the only targeted medicine to show efficacy in the treatment of early-stage lung cancer in a global trial and the first such medicine approved in China where Tagrisso reduced the risk of disease recurrence or death by 80%
AstraZeneca s Tagrisso (osimertinib) has been approved in China for the adjuvant treatment of patients with early-stage (IB, II and IIIA) epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) after tumour resection with curative intent, with or without adjuvant chemotherapy as recommended by the patient s physician. Tagrisso is indicated for EGFRm patients whose tumours have exon 19 deletions or exon 21 (L858R) mutations.
SHAREHOLDER ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ionis Pharmaceuticals, Inc prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.